EICHORCondition: Hip Fractures · Myocardial Injury · Sponsor: Population Health Research Institute
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.
This description comes directly from the study's public registry record.
Valerie Harvey · 905-297-3479 · valerie.harvey@phri.ca
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. age ≥45 years; 2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery; 3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and 4. informed consent. Exclusion Criteria: 1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe; 2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT); 3. patients with peri-prosthetic fracture, open fracture or bilateral fractures; 4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma); 5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock; 6. patients refusing consent; or 7. patients previously enrolled in HIP ATTACK-2.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Chandler Regional Medical Center | Chandler, Arizona, United States | Recruiting |
| The Regents of the University of California | Davis, California, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Emory University at Grady Memorial Hospital | Atlanta, Georgia, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Sinai Hospital of Baltimore | Baltimore, Maryland, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Lahey Hospital and Medical Center | Burlington, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Bryan Medical Center | Lincoln, Nebraska, United States | Recruiting |
| University Medical Center of Southern Nevada | Las Vegas, Nevada, United States | Recruiting |
+ 58 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04743765